Combi-elastography Assessment of HCC Recurrence After Thermal Ablation Multi-center Study

NCT04640363 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-01-15

No results posted yet for this study

Summary

Combined F index, A index,ATT index and spleen stiffness to predict tumor recurrence in different liver settings after thermal ablation of HCC.

Conditions

  • HCC
  • Recurrence Tumor

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Ping Liang, Doctor · Chinese PLA General Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2023-12-31
Completion
2024-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04640363 on ClinicalTrials.gov